Abstract
Neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease represent a crucial and exponentially increasing challenge to health care systems throughout the world. There is an urgent need for effective treatments that will both delay their onset and slow their inexorable progression. Many obstacles stand in the way of realizing these goals. It is expected that future advances will have a major impact on how and when the diagnosis will be made. It is hoped that these will eventually make it possible to initiate effective disease-modifying therapies long before the neurodegenerative process becomes established and symptomatic.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The search for, and chemistry and mechanism of, neurotrophic natural products
Journal of Natural Medicines Open Access 08 July 2020
-
Computer keyboard interaction as an indicator of early Parkinson’s disease
Scientific Reports Open Access 05 October 2016
-
Use of functional imaging across clinical phases in CNS drug development
Translational Psychiatry Open Access 16 July 2013
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
The Lewin Group. Saving lives, saving money: dividends for Americans investing in Alzheimer's Research. (Falls Church, Virginia, USA, 2004).
Alzheimer's Association. <http://www.alz.org/documents_custom/trajectory.pdf> (2010).
Alzheimer's Disease International. <http://www.alz.co.uk/research/files/WorldAlzheimerReport.pdf> (2009).
Dorsey, E.R. et al. Neurology 68, 384–386 (2007).
DeKosky, S.T. & Marek, K. Science 302, 830–834 (2003).
Brookmeyer, R., Gray, S. & Kawas, C. Am. J. Public Health 88, 1337–1342 (1998).
Olanow, C.W., Kieburtz, K. & Schapira, A.H. Ann. Neurol. 64 Suppl 2, S101–S110 (2008).
Francis, P.T., Norberg, A. & Arnold, S.E. Trends Pharmacol. Sci. 26, 104–111 (2005).
Brooks, D.J. Ann. Neurol. 44, S10–S18 (1998).
Broussolle, E. et al. Neurology 55, 877–879 (2000).
Levy, G. Arch. Neurol. 64, 1242–1246 (2007).
Levy, G. et al. Arch. Neurol. 62, 467–472 (2005).
Aarsland, D. et al. J. Neurol. 254, 38–45 (2007).
Jenner, P. Ann. Neurol. 64, S16–S29 (2008).
Dawson, T.M., Ko, H.S. & Dawson, V.L. Neuron 66, 646–661 (2010).
Ashe, K.H. & Zahs, K.R. Neuron 66, 631–645 (2010).
Epis, R. et al. Eur. J. Pharmacol. 626, 57–63 (2010).
Kokjohn, T.A. & Roher, A.E. Alzheimers Dement. 5, 340–347 (2009).
Philipson, O. et al. FEBS J. 277, 1389–1409 (2010).
Lang, A.E. Lancet Neurol. 5, 990–991 (2006).
Jucker, M. Nat. Med. published online, 10.1038/nm.2224 (21 September 2010)
Hirsch, E.C. & Hunot, S. Lancet Neurol. 8, 382–397 (2009).
Aisen, P.S. et al. Alzheimers Dement. 6, 239–246 (2010).
Trojanowski, J.Q. et al. Alzheimers Dement. 6, 230–238 (2010).
Weiner, M.W. et al. Alzheimers Dement. 6, 202–211 (2010).
Ravina, B. et al. Mov. Disord. 24, 2081–2090 (2009).
Scherzer, C.R. Neurobiol. Dis. 35, 148–156 (2009).
Hampel, H. et al. Nat. Rev. Drug Discov. 9, 560–574 (2010).
Blennow, K. Nat. Med. published online, 10.1038/nm.2221 (21 September 2010).
Blennow, K., Hampel, H., Weiner, M. & Zetterberg, H. Nat. Rev. Neurol. 6, 131–144 (2010).
Fahn, S. et al. N. Engl. J. Med. 351, 2498–2508 (2004).
Dubois, B. et al. Lancet Neurol. 6, 734–746 (2007).
Siderowf, A. & Stern, M.B. Ann. Neurol. 64, S139–S147 (2008).
Ponsen, M.M., Stoffers, D., Twisk, J.W.R., Wolters, E.C. & Berendse, H.W. Mov. Disord. 24, 1060–1065 (2009).
Haehner, A. et al. Mov. Disord. 22, 839–842 (2007).
Kieburtz, K. Neurology 66, S50–S57 (2006).
Parkinson Study Group. N. Engl. J. Med. 321, 1364–1371 (1989).
Parkinson Study Group PRECEPT Investigators et al. Neurology 69, 1480–1490 (2007)
Olanow, C.W. et al. Lancet Neurol. 5, 1013–1020 (2006).
Leber, P. Alzheimer Dis. Assoc. Disord. 11 Suppl 5, S10–S21 (1997).
Olanow, C.W. et al. Mov. Disord. 23, 2194–2201 (2008).
Clarke, C.E. Mov. Disord. 23, 784–789 (2008).
D'Agostino, R.B. Sr. N. Engl. J. Med. 361, 1304–1306 (2009).
Ploeger, B.A. & Holford, N.H. Pharm. Stat. 8, 225–238 (2009).
Parkinson Study Group et al. J. Am. Med. Assoc. 287, 1653–1661 (2002).
Whone, A.L. et al. Ann. Neurol. 54, 93–101 (2003).
Freed, C.R. et al. N. Engl. J. Med. 344, 710–719 (2001).
Olanow, C.W. et al. Ann. Neurol. 54, 403–414 (2003).
Tang, C.C., Poston, K.L., Dhawan, V. & Eidelberg, D. J. Neurosci. 30, 1049–1056 (2010).
Eckert, T., Tong, C. & Eidelberg, D. Lancet Neurol. 6, 926–932 (2007).
Lim, S.Y., Fox, S.H. & Lang, A.E. Arch. Neurol. 66, 167–172 (2009).
Huang, P. et al. Mov. Disord 24, 1732–1739 (2009).
NINDS NET-PD Investigators et al. Neurology 68, 20–28 (2007).
Salloway, S. et al. Neurology 73, 2061–2070 (2009).
Acknowledgements
I thank B. Greenberg for his helpful comments.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Lang, A. Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. Nat Med 16, 1223–1226 (2010). https://doi.org/10.1038/nm.2220
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.2220
This article is cited by
-
Magnetic Resonance Imaging Studies of Neurodegenerative Disease: From Methods to Translational Research
Neuroscience Bulletin (2023)
-
The search for, and chemistry and mechanism of, neurotrophic natural products
Journal of Natural Medicines (2020)
-
Elucidating Critical Proteinopathic Mechanisms and Potential Drug Targets in Neurodegeneration
Cellular and Molecular Neurobiology (2020)
-
Non-human primate models of PD to test novel therapies
Journal of Neural Transmission (2018)
-
Computer keyboard interaction as an indicator of early Parkinson’s disease
Scientific Reports (2016)